Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Remdesivir for the Treatment of Covid-19 - Final Report

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Monoclonal Antibody for Patients with Covid-19. Reply

    Research output: Contribution to journalLetterpeer-review

  4. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. ABO blood types and sepsis mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  • John H Beigel
  • Kay M Tomashek
  • Lori E Dodd
  • Aneesh K Mehta
  • Barry S Zingman
  • Andre C Kalil
  • Elizabeth Hohmann
  • Helen Y Chu
  • Annie Luetkemeyer
  • Susan Kline
  • Diego Lopez de Castilla
  • Robert W Finberg
  • Kerry Dierberg
  • Victor Tapson
  • Lanny Hsieh
  • Thomas F Patterson
  • Roger Paredes
  • Daniel A Sweeney
  • William R Short
  • Giota Touloumi
  • David Chien Lye
  • Norio Ohmagari
  • Myoung-Don Oh
  • Guillermo M Ruiz-Palacios
  • Thomas Benfield
  • Gerd Fätkenheuer
  • Mark G Kortepeter
  • Robert L Atmar
  • C Buddy Creech
  • Jens Lundgren
  • Abdel G Babiker
  • Sarah Pett
  • James D Neaton
  • Timothy H Burgess
  • Tyler Bonnett
  • Michelle Green
  • Mat Makowski
  • Anu Osinusi
  • Seema Nayak
  • H Clifford Lane
  • ACTT-1 Study Group Members
  • Birgitte Lindegaard Madsen (Member of study group)
  • Tomas Østergaard Jensen (Member of study group)
View graph of relations

BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.

METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.

RESULTS: A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%).

CONCLUSIONS: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).

Original languageEnglish
JournalThe New England journal of medicine
Volume383
Issue number19
Pages (from-to)1813-1826
Number of pages14
ISSN0028-4793
DOIs
Publication statusPublished - 5 Nov 2020

ID: 59909544